
Pharmaceutical company Lundbeck is naturally very pleased with the positive topline data the firm and its partner Otsuka Pharmaceuticals released for its candidate brexpiprazol on Monday morning.
Lundbeck has already started to work on a registration application to the US Food and Drug Administration (FDA) which is expected to be submitted later this year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app